Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Working Capital Changes (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Other Working Capital Changes data on record, last reported at -$782000.0 in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 1067.16% year-over-year to -$782000.0; the TTM value through Dec 2025 reached $782000.0, up 342.86%, while the annual FY2025 figure was $782000.0, 342.86% up from the prior year.
  • Other Working Capital Changes reached -$782000.0 in Q4 2025 per VRCA's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $2.4 million in Q3 2025 and bottomed at -$1.9 million in Q3 2024.
  • Average Other Working Capital Changes over 5 years is $21400.0, with a median of -$67000.0 recorded in 2023.
  • The widest YoY moves for Other Working Capital Changes: up 1240.35% in 2022, down 4030.77% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at -$57000.0 in 2021, then soared by 1240.35% to $650000.0 in 2022, then tumbled by 110.31% to -$67000.0 in 2023, then changed by 0.0% to -$67000.0 in 2024, then crashed by 1067.16% to -$782000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$782000.0 in Q4 2025, $2.4 million in Q3 2025, and -$272000.0 in Q2 2025.